Eleven years of Maraviroc experience and limited side effects in a HIV-1 experienced patient. Long term antiretroviral observation

Autor: L. E. Weimer, Giacometti A, Lucia Brescini, G Morroni, O Cirioni

Publikováno v: Clinical Case Studies and Reports. 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1241b0d8235786c9bb2c9668b8c963ce
https://doi.org/10.15761/ccsr.1000117

Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration

Autor: Silvia Baroncelli, Paola Villani, Liliana E. Weimer, Nicoletta Ladisa, Daniela Francisci, Chiara Tommasi, Vincenzo Vullo, Roberta Preziosi, Stefania Cicalini, Maria Cusato, Clementina M. Galluzzo, Marco Floridia, Mario Regazzi, for the ISS NIA Group […, R. Bucciardini, M. Floridia, LE Weimer, V. Fragola, M. Massella, S. Baroncelli, CM Galluzzo, MF Pirillo, MG Mancini, R. Amici, A. Cara, R. Bona, P. Leone, P. Filati, M. Franco, S. Donnini, M. Mirra, M. Di Gregorio, S. Lucattini, L. Fucili, F. Baldelli, D. Francisci, L. Martinelli, G. Masini, S. Bastianelli, G. Angarano, N. Ladisa, A. Volpe, V. Vullo, G. D’Ettorre, G. Ceccarelli, M. Andreoni, L. Sarmati, D. Delle Rose, M. Montano, V. Tozzi, R. Libertone, L. Pucillo, P. Narciso, R. Bellagamba, C. Tommasi, N. Petrosillo, S. Cicalini, F. Ghinelli, L. Sighinolfi, D. Segala, O. Armignacco, R. Preziosi, C. Ferrari, A. Degli Antoni, A. Cavalli, G. Parruti, F. Sozio, L. Cosentino, D. Dionisio, A. Vivarelli, PE Manconi, F. Ortu, ML Di Martino, R. Motta, R. Del Gobbo, A. Mataloni Paggi, C. Silvestri, G. Scalise, A. Giacometti, O. Cirioni, S. Sebastianelli, E. Marchionni, E. Gabrielli, MS Mura, M. Mannazzu, G. Cattari, G. Coinu, G. Guaraldi, B. Beghetto, G. Nardini, VIALE, PIERLUIGI, VERUCCHI, GABRIELLA, BORDERI, MARCO, PIERGENTILI, BENEDETTA

Publikováno v: Annals of Pharmacotherapy. 44:838-843

BACKGROUND: Raltegravir and maraviroc represent new, important resources for HIV-infected patients with intolerance or resistance to other antiretroviral agents. The safety and efficacy of both drugs have been investigated, but there is no informatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb2e87cc2268a611143d40299c84ad6
https://doi.org/10.1345/aph.1m688

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats

Autor: Jerzy Lukasiak, Federico Mocchegiani, Giuseppina D'Amato, G. Scalise, O. Cirioni, Andrea Giacometti, Roberto Ghiselli, Vittorio Saba, Wojciech Kamysz, M Simona Del Prete, Fiorenza Orlando

Publikováno v: Gut. 52:874-878

Background: Postoperative morbidity in patients with obstructive jaundice remains high because of increased susceptibility to endotoxin and the inflammatory cascade. Aims: An experimental study was designed to investigate the efficacy of protegrin pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::229ae0fdfb318f806a34942e376ec54a
https://doi.org/10.1136/gut.52.6.874

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.